Grifols SA operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Grifols SA with three other
pharmaceutical manufacturers in Europe:
sales of 5.35 billion Euros [US$6.20 billion]
of which 34%
(3.12 billion Euros [US$3.62 billion]
of which 85%
was Diagnostic Clinical Equipment), and
Lonza Group AG
based in SWITZERLAND
(4.51 billion Swiss Francs [US$4.88 billion]
of which 99%
During the second
quarter of 2021, sales at Grifols SA totalled
1.35 billion Euro.
This is a drop of 2.3%
from the 1.38 billion Euro in sales at the company during the second quarter in 2020.
During the first two
quarters of 2021, sales totalled 2.54 billion Euro, which is
than through the first two quarters of 2020.
Grifols SA reported sales of 5.34 billion Euro (US$6.19 billion)
December of 2020.
increase of 4.7%
versus 2019, when the company's sales were 5.10 billion Euro.
Sales at Grifols SA have increased during each of the previous five years
(and since 2015, sales have increased a total of 36%).
Sales of Others/raw Materials saw an increase
that was more than double the company's growth rate: sales were up
40.2% in 2020, from
22.82 million Euro to 31.99 million Euro.
Grifols SA also saw significant increases in sales in
Bioscience (up 6.2% to 4.24 billion Euro)
Not all segments of Grifols SA experienced an increase in sales in 2020:
sales of Bio Supplies fell 15.9% to 224.09 million Euro.
Grifols SA also experienced decreases in sales in
Hospital (down 11.7% to 118.68 million Euro)